首页|期刊导航|中国实用神经疾病杂志|替奈普酶与阿替普酶静脉溶栓治疗高龄急性缺血性脑卒中患者的对比研究

替奈普酶与阿替普酶静脉溶栓治疗高龄急性缺血性脑卒中患者的对比研究OA

Comparative study of tenecteplase versus alteplase in intravenous thrombolytic therapy for elderly patients with acute ischemic stroke

中文摘要英文摘要

目的 对比高龄急性缺血性脑卒中(AIS)患者采取替奈普酶(TNK)和阿替普酶(rt-PA)静脉溶栓治疗的安全性与有效性.方法 纳入2023-01-2025-01就诊于邢台市中心医院神经内科的403例高龄AIS患者进行回顾性研究,按治疗方法分为实验组(TNK静脉溶栓,204例)和对照组(rt-PA静脉溶栓,199例).实验组中年龄75~<80岁的患者归入组1(152例),年龄≥80岁的患者归入组2(52例);对照组中年龄75~<80岁的患者归入组3(149例),年龄≥80岁的患者归入组4(50例).比较治疗前后各组症状性颅内出血(sICH)发生率、全身出血事件发生率、48 h病死率、90 d病死率、D-二聚体、C反应蛋白(CRP)、N末端B型钠尿肽前体(NT-proBNP)、基质金属蛋白酶-9(MMP-9)、胶质纤维酸性蛋白(GFAP)、90 d mRS≤2的患者比例、24 h NIHSS改善率、90 d血管再通率及住院时间.结果 实验组与对照组患者sICH发生率、全身出血事件发生率、48 h病死率以及90 d病死率均无统计学差异(P>0.05).溶栓前,2组患者D-二聚体、CRP、NT-proBNP、MMP-9及GFAP水平均无统计学差异(P>0.05),溶栓后,各组D-二聚体、NT-proBNP均显著降低,且实验组显著低于对照组(P<0.05),各组MMP-9、GFAP、CRP水平均显著升高,对照组显著高于实验组(P<0.05).实验组90dmRS≤2的患者比例及90 d血管再通率显著高于对照组(P<0.05),2组24 h NIHSS改善率及住院时间无统计学差异(P>0.05).结论 对于高龄AIS患者,TNK静脉溶栓治疗的安全性与rt-PA相当,在改善远期神经功能预后及促进血管再通方面更具优势.TNK在高龄患者中可能通过减轻炎症反应和神经细胞损伤发挥效果.

Objective To compare the safety and efficacy of tenecteplase(TNK)versus alteplase(rt-PA)for intravenous thrombolysis in elderly patients with acute ischemic stroke(AIS).Methods A retrospective study was conducted involving 403 elderly patients with AIS admitted to the Department of Neurology,Xingtai Central Hospital between January 2023 and January 2025.Participants were divided into experimental group(intravenous TNK thrombolysis,n=204)and control group(intravenous rt-PA thrombolysis,n=199)based on treatment modality.Within the experimental group,patients aged<80 years were categorized as Group 1(n=152)and those aged ≥80 years as Group 2(n=52).In the control group,patients aged<80 years comprised Group 3(n=149)and those aged ≥80 years Group 4(n=50).The following parameters were compared across groups:symptomatic intracranial hemorrhage(sICH)incidence,systemic bleeding event incidence,48-hour mortality,90-day mortality;Biomarker levels:D-dimer,C-reactive protein(CRP),N-terminal pro-B-type natriuretic peptide(NT-proBNP),matrix metalloproteinase-9(MMP-9),glial fibrillary acidic protein(GFAP),proportion of patients with modified Rankin scale(mRS)score ≤2 at 90 days,24-hour NIHSS improvement rate,90-day revascularization rate,the length of hospital stay.Results No significant differences were observed between the experimental group and the control group in sICH incidence,systemic bleeding events,48-hour mortality,or 90-day mortality(P>0.05).No significant intergroup differences in D-dimer,CRP,NT-proBNP,MMP-9,or GFAP levels pre-thrombolysis(P>0.05).After thrombolysis,D-dimer and NT-proBNP levels decreased significantly in both groups,with lower values in the experimental group(P<0.05).MMP-9,GFAP,and CRP levels increased significantly in all groups,but were markedly higher in the control group(P<0.05).The experimental group demonstrated significantly higher rates of favorable functional outcome(mRS ≤2 at 90 days)and revascularization(P<0.05).No significant differences were found in 24-hour NIHSS improvement rates or length of hospitalization(P>0.05).Conclusion For elderly AIS patients,TNK demonstrates comparable safety to rt-PA but offers superior long-term neurological outcomes and vascular recanalization.The advantages of TNK may be attributed to its greater efficacy in reducing the expression of neurotoxic biomarkers and inflammatory responses.

孟燕;庞玉明;王玮玮;吴雷朋;魏玉清

邢台市中心医院,河北邢台 054000邢台市第一医院,河北邢台 054001邢台市中心医院,河北邢台 054000邢台市中心医院,河北邢台 054000邢台市中心医院,河北邢台 054000

医药卫生

急性缺血性脑卒中高龄替奈普酶阿替普酶静脉溶栓

Acute ischemic strokeElderlyTenecteplaseAlteplaseIntravenous thrombolysis

《中国实用神经疾病杂志》 2026 (1)

68-73,6

邢台市重点研发计划自筹项目(编号:2025ZC357)

10.12083/SYSJ.250912

评论